MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of colorectal cancer

International Journal of Medical Sciences

Volumn 8, Issue 1, 2011, Pages 39-47

  Liu, Chibo ^a   Pan, Chunqin ^a   Shen, Jianmin ^a   Wang, Haibao ^a   Yong, Liang ^a  

^a Taizhou Municipal Hospital   (China)

Author keywords

Biomarker; Colorectal cancer; MALDI; Protein; Serum

Indexed keywords

BIOLOGICAL MARKER; MAGNETIC NANOPARTICLE; NANOBEAD;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CATION EXCHANGE; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; COLORECTAL CANCER; COMPUTER MODEL; CONTROLLED STUDY; DECISION TREE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOWN REGULATION; FUNCTIONAL PROTEOMICS; HUMAN; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; NANODEVICE; ONSET AGE; PHASE SEPARATION; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; UPREGULATION;

EID: 79851494677     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.8.39     Document Type: Article

References (42)

1. [Internet] WHO. Global cancer rates could increase by 50%to 15 million by 2020. http://www.who.int/mediacentre/news/releases/2003/pr27/en/
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581-92.
3. Davila RE, Rajan E, Baron TH, et al. ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc.2006; 63:546-57.
4. Karakosta A, Golias Ch, Charalabopoulos A, et al. Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia. J Exp Clin Cancer Res.2005; 24(4):505-14.
5. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst.2004; 96(19):1420-5.
6. Australian Institute of Health and Welfare (AIHW), Australasian Association of Cancer Registries (AACR). Cancer in Australia. In: Cancer in Australia 2001; Cancer series number 28. Canberra: Australian Institute of Health and Welfare. 2004: 6-25.
7. Huh JW, Park YA, Lee KY, et al. Recurrences after local excision for early rectal adenocarcinoma. Yonsei Med J.2009; 50:704-8.
8. Faerden AE, Naimy N, Wiik P, et al. Total mesorectal excision for rectal cancer: difference in outcome for low and high rectal cancer. Dis Colon Rectum.2005; 48: 2224-2231.
9. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med.1986; 104: 66-73.
10. Hardcastle JD, Thomas WM, Chamberlain J, et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects.Lancet.1989; 1:1160-4.
11. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet.1996; 348:1467-71.
12. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology.2000; 119: 1219-1227.
13. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst.2001; 93: 858-865.
14. Leslie A, Pratt NR, Gillespie K, et al. Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. Cancer Res. 2003; 63:4656-4661.
15. Slack GW, Wizniak J, Dabbagh L, et al. Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis.Arch Pathol Lab Med.2007; 131:50-56.
16. von Eggeling F, Davies H, Lomas L, et al. Tissue-specific microdissection coupled with ProteinChip array technologies: applications in cancer research. Biotechniques.2000; 29: 1066-1070.
17. Zhukov TA, Johanson RA, Cantor AB, et al. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer.2003; 40: 267-279.
18. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol.2001; 158: 1491-15021.
19. Barillari P, Ramacciato G, de Angelis R, et al. The role of CEA, TPA and CA 19-9 in the early detection of recurrent colorectal cancer. Int J Colorectal Dis. 1989; 4:230-233.
20. Rodland KD. Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin Biochem.2004; 37:579-583.
21. Conrads TP, Hood BL, Issaq HJ, Veenstra TD. Proteomic patterns as a diagnostic tool for early-stage cancer: a review of its progress to a clinically relevant tool. Mol Diagn.2004; 8:77-85.
22. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol. 2004; 15:24-30.
23. Walsh PC. Serum proteomic patterns for detection of prostate cancer. J Urol. 2003;169:1592.
24. Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin.Cancer.Res.2005; 11:1073-1085.
25. Zeidan BA, Townsend PA. SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res. 2008;10:107.
26. Langbein S, Lehmann J, Harder A, Steidler A, Michel MS. Protein profiling of bladder cancer using the 2D-PAGE and SELDI-TOF-MS technique. Technol.Cancer Res.Treat.2006; 5:67-72.
27. Paradis V, Degos F, Dargère D, Pham N, Belghiti J. Identification of a new marker of hepatocellu1ar carcinom a by serum protein profiling of patients with chronic liver diseases. Hepatology. 2005; 41:40-47.
28. Cho WC, Yip TT, Ngan RK, Yip TT, Podust VN. ProteinChip array profiling for identification of disease- and chemotherapy- associated biomarkers of nasopharyngeal carcinoma. Clin Chem. 2007; 53:241-250.
29. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosi. Proc.Natl.Acad.Sci.USA.2003; 100:12343-12348.
30. Roessler M, Rollinger W, Palme S, Hagmann ML, Berndt P, Engel AM, Schneidinger B, Pfeffer M, Andres H, Karl J, Bodenmüller H, Rüschoff J, Henkel T, Rohr G, Rossol S, R?sch W, Langen H, Zolg W, Tacke M. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res.2005; 11(18):6550-7.
31. Ma Y, Peng J, Huang L, Liu W, Zhang P, Qin H. Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis.2009; 30(15):2591-9.
32. Roessler M, Rollinger W, Mantovani-Endl L, Hagmann ML, Palme S, Berndt P, Engel AM, Pfeffer M, Karl J, Bodenmüller H, Rüschoff J, Henkel T, Rohr G, Rossol S, R?sch W, Langen H, Zolg W, Tacke M. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics.2006; 5(11):2092-2101.
33. Ma Y, Peng J, Liu W, Zhang P, Huang L, Gao B, Shen T, Zhou Y, Chen H, Chu Z, Zhang M, Qin H. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol Cell Proteomics.2009; 8(8):1878-90.
34. Alessandro R, Belluco C, Kohn EC. Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clin Colorectal Cancer. 2005; 4(6):396-402.
35. Cho WC. Research progress in SELDI-TOF MS and its clinical applications. Chin J Biotech, 2006, 22(6): 871-876.
36. Cho WC. Proteomics technologies and challenges. Genomics Proteomics Bioinformatics 2007; 5:77-85.
37. Liao CC, Mehta A, Ward NJ, Marsh S, Arulampalam T, Norton JD. Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study. World J Surg Oncol. 2010;8:33.
38. Cho WC and Cheng CH. Oncoproteomics: current trends and future perspectives. Expert Rev Proteomics 2007; 4:401-410.
39. Ma Y, Zhao M, Zhong J, Shi L, Luo Q, Liu J, Wang J, Yuan X, Huang C. Proteomic profiling of proteins associated with lymph node metastasis in colorectal cancer. J Cell Biochem. 2010;110(6):1512-9.
40. Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer. 2007;6:25.
41. Liao CC, Ward N, Marsh S, Arulampalam T, Norton JD. Mass spectrometry protein expression profiles in colorectal cancer tissue associated with clinico-pathological features of disease. BMC Cancer. 2010;10:410.
42. Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004; 10:43-52.